Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Novo Nordisk GlucaGen · 1 trial · 1 indication
The onset of action was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucose following each dose of glucagon.
The speed of absorption was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucagon following each dose of glucagon.
| Arm | Type | Description |
|---|---|---|
| G-Pump™ (glucagon infusion) | EXPERIMENTAL | G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg |
| Novo Nordisk GlucaGen® | ACTIVE_COMPARATOR | Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg |
| Name | Type | Description |
|---|---|---|
| Novo Nordisk GlucaGen® | DRUG | single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg |
| G-Pump™ (glucagon infusion) | DRUG | single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg |
Inclusion Criteria: * Males or females diagnosed with type 1 diabetes mellitus for at least 24 months * Current usage of subcutaneous insulin pump treatment * Age 18-65 years * C-peptide level \< 0.5 ng/ml * Willingness to follow all study procedures, including attending all clinic visits * Subject...
Novo Nordisk GlucaGen is a glucagon-based therapy being studied for hypoglycemia, or low blood sugar. It is being evaluated in patients with type 1 diabetes who are at risk of hypoglycemia. The development program focuses on metabolic conditions.
Novo Nordisk GlucaGen is being developed by Xeris Biopharma Holdings, Inc., which trades on the Nasdaq under the ticker XERS. Xeris is advancing the program in the metabolic therapeutic area.
Novo Nordisk GlucaGen is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. The program has completed one Phase 2 trial.
Novo Nordisk GlucaGen has been studied in one completed Phase 2 trial, NCT02081001, titled PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients. The trial enrolled 19 participants in the United States and evaluated hypoglycemia in type 1 diabetes.
Yes, Novo Nordisk GlucaGen and Novo Nordisk GlucaGen® refer to the same therapy. The registered trademark symbol is simply part of the product name.